NCT00333190View on ClinicalTrials.gov

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2009

Conditions
Hematologic MalignancyAMLALLCMLMultiple MyelomaNHLHodgkin's Lymphoma
Interventions
DEVICE

CD+8 T cell depletion

CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Brigham and Women's Hospital

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00333190 - CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation | Biotech Hunter | Biotech Hunter